position: 首页 Faculty> pharmaceutics> Content

pharmaceutics

Man Li

Source: Date:2023-02-21Click:

Man Li, Associate Professor, Graduate Supervisorundefined 

 

Affiliation: Department of Pharmaceutics, West China School of Pharmacy, Sichuan University

AddressNo.17, Section 3, South Renmin Road, Chengdu, China, 610041

E-mail: manli@scu.edu.cn

 

Education and Working Experience

2006.09-2010.06 Bachelor of Science, National Key Course of Biotechnology, School of Life Science, Sichuan University

2010.09-2013.06 Master of Science, Department of Pharmaceutics, West China School of Pharmacy, Sichuan University. Tutor: Professor Zhirong Zhang

2013.09-2016.06 Ph.D, Department of Pharmaceutics, West China School of Pharmacy, Sichuan University. Tutor: Professor Zhirong Zhang

2016.07-2020.09 Post doctorial researcher, Department of Pharmaceutics, West China School of Pharmacy, Sichuan University. Tutor: Professor Qin He

2020.09-Now Associate Professor, Department of Pharmaceutics, West China School of Pharmacy, Sichuan University

2021.07-Now Graduate supervisor, Department of Pharmaceutics, West China School of Pharmacy, Sichuan University

 

Research Interest

Design and mechanism study of novel drug delivery systems

 

Academic Service

Editorial board member of European Journal of Pharmaceutics and Biopharmaceutics

Young director of Chinese Society of Granular Science Association

 

Projects

1. General Program of National Natural Science Foundation of China, 82173771, 2022.01-2025.12, 550,000 Yuan

2. National Natural Science Foundation of China for Young Scholars817034502018.01-2020.12, 201,000 Yuan

3. National Natural Science Foundation of Sichuan Province for Young Scholars, 2022NSFSC1523, 2022.1-2023.12, 100,000 Yuan

4. Youth Foundation of Science and Technology Bureau of Sichuan Province, 2019JDRC0097, 2019.01-2021.01, 100,000 Yuan

5. Interdisciplinary Foundation of Sichuan University, 2019-2021, 200,000 Yuan

6. Special Program of China Postdoctoral Science Foundation2018T1109852018-2020150,000 Yuan

7. General Program of China Postdoctoral Science Foundation (1st prize), 2017M620429, 2017-2019, 80,000 Yuan

8. Post-doctoral Foundation of Sichuan University, 2018.01-2019.12, 150,000 Yuan

9. General Program of National Natural Science Foundation of China, 81690261, 2017.1-2021.12, 3,326,000 Yuan (Participated)

 

Selected Publications

1. Qinglin Sheng, Ting Li, Xian Tang, Wei Zhao, Rong Guo, Xingli Cun, Shuya Zang, Zhirong Zhang, Man Li* and Qin He*. Comprehensively enhanced delivery cascade by transformable beaded nanofibrils for pancreatic cancer therapy. Nanoscale, 2021, 13, 13328.

2. Xiaoxiao Chen1, Yuan Tao1, Manmin He, Miao Deng, Rong Guo, Qinglin Sheng, Xuhui Wang, Kebai Ren, Ting Li, Xuan He, Shuya Zang, Zhirong Zhang, Man Li* and Qin He*. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Theranostics 2021, 11, 18, 8692-8705.

3. Junyu Wu, Yang Long, Man Li*, Qin He*. Emerging nanomedicine-based therapeutics for hematogenous metastatic cascade inhibition: Interfering with the crosstalk between “seed and soil”. Acta Pharmaceutica Sinica B, 2021,11(8), 2286-2305.

4. Man Li, Mengmeng Li, Yiliang Yang, Yingke Liu, Hanbing Xie, Qianwen Yu, Lifeng Tian, Xian Tang, Kebai Ren, Jianping Li, Zhirong Zhang, Qin He*. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. Journal of Controlled Release, 2020, 321, 23-35.

5. Xingli Cun, Jiantao Chen, Mengmeng Li, Xuan He, Xian Tang, Rong Guo, Miao Deng, Man Li*, Zhirong Zhang, Qin He*. Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle. ACS Applied Materials & Interfaces, 2019, 11, (43), 39545-39559.

6. Rong Guo,Yang Long, Zhengze Lu, Miao Deng, Penghui He, Man Li*, Qin He*. Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS. Acta Pharmaceutica Sinica B, 2020, 10, 10, 1977-1988.

7. Jiaojie Wei, Yang Long, Rong Guo, Xinlei Liu, Xian Tang, Jingdong Rao, Sheng Yin, Zhirong Zhang, Man Li*, Qin He. Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharmaceutica Sinica B 2019; 9(4): 819–831.

8. Man Li, Hanbing Xie, Yingke Liu, Chunyu Xia, Xingli Cun, Yang Long, Xiaoxiao Chen, Miao Deng, Rong Guo, Zhirong Zhang, Qin He*. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer. Journal of Controlled Release, 2019, 304, 204-215.

9. Man Li, You Li, Ke Peng, Ying Wang, Tao Gong, Zhirong Zhang, Qin He, Xun Sun*. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomaterialia, 2017, 64, 237-248.

10. Man Li, Mengnan Zhao, Yao Fu, You Li, Tao Gong, Zhirong Zhang, Xun Sun. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. Journal of Controlled Release, 2016,228, 9-19.

 

Next article:Qing Lin

Address: No. 17, Section 3, Southern Renmin Rd. Chengdu 610041 China

Tel/fax: +86-28-85501628

Email: yxyban@163.com

Today's traffic: